Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $44.25

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been given a consensus rating of “Moderate Buy” by the eleven research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $44.25.

A number of research analysts have commented on STOK shares. Chardan Capital reaffirmed a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Tuesday, August 4th. BTIG Research reiterated a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a report on Monday, May 11th. Guggenheim reissued a “buy” rating and set a $60.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. JPMorgan Chase & Co. started coverage on Stoke Therapeutics in a research note on Friday, August 21st. They set an “overweight” rating and a $40.00 price objective on the stock. Finally, The Goldman Sachs Group started coverage on shares of Stoke Therapeutics in a report on Monday, July 13th. They issued a “buy” rating and a $44.00 price objective for the company.

Stoke Therapeutics Price Performance

STOK opened at $29.81 on Friday. Stoke Therapeutics has a 12-month low of $19.55 and a 12-month high of $40.22. The stock has a market capitalization of $1.92 billion, a PE ratio of -8.93 and a beta of 1.23. The firm’s fifty day moving average price is $31.17 and its 200 day moving average price is $32.20.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.13). Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%.The company had revenue of $9.32 million for the quarter, compared to analyst estimates of $4.89 million. On average, equities research analysts forecast that Stoke Therapeutics will post -3.52 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Edward Kaye sold 12,567 shares of Stoke Therapeutics stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total value of $402,521.01. Following the completion of the transaction, the director directly owned 124,557 shares of the company’s stock, valued at approximately $3,989,560.71. The trade was a 9.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Jonathan Allan sold 2,861 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total transaction of $91,637.83. Following the sale, the general counsel directly owned 21,225 shares of the company’s stock, valued at approximately $679,836.75. This represents a 11.88% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 34,373 shares of company stock valued at $1,068,939. Company insiders own 9.60% of the company’s stock.

Institutional Trading of Stoke Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Hussman Strategic Advisors Inc. bought a new position in Stoke Therapeutics during the 4th quarter worth $2,000,000. Dimensional Fund Advisors LP increased its position in Stoke Therapeutics by 19.7% in the first quarter. Dimensional Fund Advisors LP now owns 989,936 shares of the company’s stock worth $32,229,000 after buying an additional 162,797 shares during the period. Janus Henderson Group PLC lifted its stake in Stoke Therapeutics by 11.2% in the first quarter. Janus Henderson Group PLC now owns 1,612,781 shares of the company’s stock valued at $52,456,000 after buying an additional 161,848 shares during the last quarter. Candriam S.C.A. lifted its stake in Stoke Therapeutics by 12.4% in the first quarter. Candriam S.C.A. now owns 502,020 shares of the company’s stock valued at $16,346,000 after buying an additional 55,330 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Stoke Therapeutics by 163.4% during the first quarter. Bank of America Corp DE now owns 543,095 shares of the company’s stock valued at $17,683,000 after acquiring an additional 336,931 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.